COMMENTARY

• Tougher Pricing Policy, New Products Essential to Offset Impact of NHI Price Revision
  March 27, 2006

• No Domestic Company Moves Despite Expected Growth: Vaccine Business
  March 27, 2006

• FY2006 NHI Price Revision: Industry Succeeds in Defensive Efforts
  March 13, 2006

• Effects of Medical Fee Revision Need to be Verified
  March 6, 2006

• Pfizer Management, Labor See Signs of Snowbreak
  March 6, 2006

• ＜COMMENTARY＞　New Dispensing Fees Nearly Decided
  February 20, 2006

• Japan's Most Admired Pharma Companies　P. Reed Maurer
  February 20, 2006

• Frustrating Outcome for Industry: Exceptional NHI Price Reduction for Long-listed Drugs
  February 13, 2006

• Requirements for External IRBs to Be Relaxed
  February 13, 2006

• Astellas' Inventorship Issue with Professor Ochiai - What If This Were a US Case?
  February 6, 2006

• COMMENTARY 2 articles
  January 30, 2006

• JPLA SEMINAR
  January 30, 2006

• Maurer's Healthcare Insight (72)
  January 30, 2006

• Astellas' Inventorship Issue with Professor Ochiai - What If This Were a US Case?
  January 30, 2006

• Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II)　-2-
  January 30, 2006

• Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (II)　-1-
  January 30, 2006

• From "Replacement" to "Addition": Prescription Form
  January 23, 2006

• Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (I)　－２－
  January 23, 2006

• Vascular Calcification: Ultimate Consequnce of Vascular Atherosclerosis (I)　－１－
  January 23, 2006

• A Happy Year 2006 to Japanese Pharmaceutical Stocks!
  January 23, 2006

ページ